Odevixibat (progressive familial intrahepatic cholestasis (PFIC) in patients aged ≥ 6 months)

Subject:

• Active Substance: Odevixibat
• Name: Bylvay^®
• Therapeutic area: Cholestasis
• Pharmaceutical company: Albireo Pharma AB

Time table:

• Start: 15.09.2021
• Final decision by G-BA: beginning of March 2022
• This decision remains valid until: 01.06.2027

Final decision:

• Hint for a minor additional benefit (orphan drug)